InventivaIVA -6.36%40 ROA % is -167.46% as of Dec. 2025. GuruFocus rates IVA with a GF Score™ of 40/100 and a GF Value™ of $0.29 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,423 Biotechnology companies, Inventiva ranks worse than 93.53% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Inventiva's annualizedNet Income for the quarter that ended in Dec. 2025 was $-417.46 Mil.
Inventiva's average Total Assets over the quarter that ended in Dec. 2025 was $249.29 Mil. Therefore, Inventiva's annualized ROA % for the quarter that ended in Dec. 2025 was -167.46%.
The historical rank and industry rank for Inventiva's ROA % or its related term are showing as below:
IVA'
s ROA % Range Over the Past 10 Years
Min: -195.42 Med: -43.51 Max: -12.86
Current: -194.07
During the past 13 years, Inventiva's highest ROA % was -12.86%. The lowest was -195.42%. And the median was -43.51%.
IVA's ROA % is ranked worse than 93.53% of 1423
companies
in the Biotechnology industry
Industry Median: -32.9
vs IVA: -194.07
Inventiva (NAS:IVA) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Inventiva ROA % Related Terms
Inventiva ROA % Historical Data
* Premium members only.
The historical data trend for Inventiva's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inventiva's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inventiva ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inventiva's ROA % distribution charts can be found below:
* The bar in red indicates where Inventiva's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Inventiva (IVA) has a ROA % of -167.46% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Inventiva and its competitors. According to the industry distribution chart, Inventiva ranks #1331 out of 1423 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Inventiva's ROA % too high?
Inventiva's current ROA % is -167.46%. Based on the distribution chart, Inventiva ranks #1331 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inventiva has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #1331 out of 1423 companies for ROA %. This places Inventiva in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Inventiva and its competitors. Inventiva's current ROA % is -167.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (IVA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $3.48 — trading 1100% above its estimated fair value. The current ROA % is -167.46%. Inventiva's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Inventiva (IVA), the current ROA % is -167.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inventiva (IVA) Overvalued in 2026?
Based on GuruFocus' analysis, Inventiva stock appears to be overvalued.
The current stock price of $3.48 is trading 1100% above its estimated GF Value™ of $0.29.
GuruFocus considers Inventiva to be Significantly Overvalued.
Key valuation signals for IVA:
ROA %: -167.46%
GF Value™: $0.29 vs. price of $3.48 (1100% above fair value)
No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score
Get the complete analysis for IVA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVA has been successfully added to your 
